The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?

Jan 20, 2020
Share:

The MPN Hub were pleased to speak to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?

Jacqueline S. Garcia comprehensively discusses a phase II clinical trial that added the BH3 mimetic, navitoclax, to ruxolitinib treatment in patients with myelofibrosis to increase patient response rate with this combination. She discusses the patient inclusion criteria, treatment regimen, safety, response rates, primary endpoints and overall outcome to this novel combination. She concludes by stating that this novel combination looks to be highly encouraging in producing clinically meaningful outcomes.

Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?

Share: